Phendimetrazine Shortage Update: What Patients Need to Know in 2026

If you've been having trouble filling your Phendimetrazine prescription at local pharmacies in 2026, you're not imagining things. While Phendimetrazine is not listed on the FDA's official drug shortage database, patients across the country continue to run into empty shelves — especially at large chain pharmacies.

Here's everything you need to know about the current supply situation, what's causing it, and what you can do to get your medication filled.

What Is the Current Status of Phendimetrazine Supply in 2026?

As of early 2026, Phendimetrazine is NOT on the FDA's official drug shortage list. Manufacturers are reporting production of both the immediate-release 35 mg tablets and the extended-release 105 mg capsules. However, this official designation doesn't always reflect what patients experience at the pharmacy counter.

What patients are experiencing is more accurately described as "distribution-level unavailability" — the drug is being made, but it's not consistently reaching every pharmacy, particularly large chain locations.

What's Causing the Supply Problems?

Several overlapping factors are responsible:

• DEA Schedule III production quotas: As a Schedule III controlled substance, Phendimetrazine can only be manufactured in amounts approved by the DEA. Annual quotas limit how much can be produced, and increasing them requires a formal application process that can take months.
• Brand discontinuation: Brand-name Bontril PDM and Bontril Slow Release were discontinued in the U.S. market. The generic-only market is served by a small number of manufacturers, creating concentration risk.
• Surging demand for weight-loss medications: The national conversation around weight management has intensified since 2022. Even as GLP-1 medications dominate headlines, older oral options like Phendimetrazine have seen renewed interest from patients seeking affordable alternatives.
• Low chain pharmacy stocking: Many chain pharmacies don't keep Phendimetrazine in regular stock because it's a niche controlled substance with limited prescription volume per location. When demand spikes locally, these pharmacies run out quickly.

Has Phendimetrazine Been Discontinued?

No. Generic Phendimetrazine — both the 35 mg immediate-release tablet and 105 mg extended-release capsule — remains on the U.S. market as of 2026. The drug has not been pulled from the FDA formulary. What HAS been discontinued are the specific brand-name versions (Bontril PDM and Bontril Slow Release). Generic versions continue to be available.

How Does This Shortage Compare to Other Weight-Loss Medications?

Phendimetrazine is not alone. The broader weight-loss medication landscape has experienced significant supply pressures in recent years:

• GLP-1 medications (Wegovy, Zepbound) have faced their own multi-year shortages driven by unprecedented demand
• Phentermine has experienced localized supply gaps despite not being on the FDA shortage list
• Benzphetamine (Didrex) has faced more severe shortages due to even more limited manufacturing

In this context, Phendimetrazine's supply situation is not catastrophic — but it does require patients to be more proactive than they would be for a widely available generic medication.

What Patients Can Do Right Now

Here are the most effective steps patients can take:

1. Use medfinder to check which pharmacies near you have Phendimetrazine in stock before making any trips. Visit medfinder.com to get started.
2. Try independent pharmacies — they typically stock and reorder Phendimetrazine more reliably than large chains.
3. Ask about both formulations — the 35 mg tablets and 105 mg ER capsules may have different availability at the same pharmacy.
4. Plan refills 5-7 days early to avoid running out while searching for stock.
5. Talk to your doctor about alternatives if supply issues persist. See our guide to Phendimetrazine alternatives for a full breakdown.